A new report contends that upgrading Medicaid drug benefit programs would save $74.4 billion over 10 years without reducing benefits or the number of enrollees.

The Pharmaceutical Care Management Association sponsored the study, which consulting firm The Menges Group conducted. Savings in the report would total $43 billion to the federal government and $31.4 billion to states.

The savings would include $23.5 billion by increasing use of generic drugs, $12.5 billion by negotiating market-based pharmacy dispensing fees, $33.4 billion by using limited pharmacy networks, $2.7 billion by encouraging use of more affordable preferred brands, and $2.3 billion from reducing drug diversion, polypharmacy (patients prescribed too many medications with too little coordination), fraud and waste.

The report is available here.

Register or login for access to this item and much more

All Health Data Management content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access